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Purpose of review: Update findings regarding polypharmacy among people with HIV (PWH) and 
consider what research is most needed. 
Recent findings: Among PWH, polypharmacy is common, occurs in middle age, and is 
predominantly due to non-antiretroviral (ARV) medications. Many studies have demonstrated 
strong associations between polypharmacy and receipt of potentially inappropriate 
medications (PIMS), but few have considered actual adverse events. Falls, delirium, pneumonia, 
hospitalization, and mortality are associated with polypharmacy among PWH and risks remain 
after adjustment for severity of illness. 
Summary: Polypharmacy is a growing problem and mechanisms of injury likely include 
potentially inappropriate medications, total drug burden, known pairwise drug interactions, 
higher level drug interactions, drug-gene interactions, and drug-substance use interactions 
(alcohol, extra-medical prescription medication, and drug use ). Before we can effectively 
design interventions, we need to use observational data to gain a better understanding of the 
modifiable mechanisms of injury. Because sicker individuals take more medications, analyses 
must account for severity of illness. Because self-report of substance use may be inaccurate, 
direct biomarkers such as phosphatidylethanol (PEth) for alcohol are needed. Large samples 
including electronic health records, genetics, accurate measures of substance use, and state of 
the art statistical and artificial intelligence techniques are needed to advance our 
understanding and inform clinical management of polypharmacy in PWH. 
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Polypharmacy, often defined as concurrent use of five or more medications, is a growing 
concern among people with HIV (PWH). After antiretroviral (ARV) treatment initiation, typically 
requiring three ARV medications, many non-ARV medications are prescribed to address 
symptoms, side effects, and to treat or prevent comorbid disease. An estimated 15% to 39% of 
PWH are exposed to polypharmacy(1-6), with higher rates in resource rich settings and among 
older individuals(7). Of note, while polypharmacy is often measured as a threshold  (five 
medications), total medication count must also be considered; each additional medication 
increases risk for interactions and potential adverse events. 
 
Polypharmacy presents unique management issues for PWH(8) and clinical guidelines 
emphasize its importance in caring for adults with HIV(9, 10). PWH are exposed to 
polypharmacy a decade earlier than the general population. ARV medications interact with 
commonly prescribed non-ARV medications(11) and PWH may be more susceptible to 
medication side effects due to increased physiologic frailty. Finally, polypharmacy itself may 
decrease ARV adherence, threatening the patient’s ability to maintain viral suppression.  
 
Herein, we highlight recent advances based on literature published from 2017 through October 
2019 on polypharmacy in PWH. Based on these studies, we discuss recent insights regarding 
polypharmacy among PWH including 1) prevalence; 2) associated adverse events; and 3) 




Prevalence of Polypharmacy Among PWH   
Compared to those without HIV, PWH are more likely to be exposed to polypharmacy at 
younger ages, especially when non-prescription medications, complementary and alternative 
medicine (CAM), and extra-medical use of prescription medications (i.e., use of medications in 
way other than prescribed by a clinician and also referred to as “non-medical” or “misuse”)(12) 
are included (3, 13-15). In addition to ARVs, polypharmacy among PWH is driven by non-ARV 
medications(3, 6, 16). We used fiscal year 2018 data from the Veterans Aging Cohort Study, a 
national study of all patients with HIV receiving healthcare within the Veterans Affairs 
Healthcare System, matched to demographically similar controls,  to provide a recent snapshot 
(Table 1) of non-ARV polypharmacy. A comparison of prescription medications by HIV status 
demonstrates that many of the same medications are common in both groups and that 
antihypertensives, statins, antidepressants, opioid and non-opioid analgesics, erectile 
dysfunction medications, anticonvulsants, proton pump inhibitors, and hypoglycemic 
medications top the list. 
 
Few studies have examined longitudinal patterns of polypharmacy within individuals. Ware and 
colleagues used data from the Multicenter AIDS Cohort Study, a cohort of men who have sex 
with men with and without HIV(14), to identify patterns of polypharmacy over time. Among 
PWH, four unique patterns of polypharmacy were identified based on an average follow-up of 
12 years: non-polypharmacy (49%); slowly increasing polypharmacy (25%); rapidly increasing 
polypharmacy (12%); and sustained polypharmacy (14%). Among PWH, factors independently 
associated with increased likelihood of membership in the sustained polypharmacy compared 
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to non-polypharmacy group included public insurance, earlier study enrollment, having a 
college degree or higher, and health care visits (i.e., visits to a physician’s office, emergency 
department or other health care clinic use). Presence of a detectable HIV viral load was 
associated with decreased likelihood of membership in the sustained polypharmacy group, 
suggesting that polypharmacy typically begins after ARV initiation, which is a hallmark of 
engagement in HIV care and after which attention often pivots to diagnosis and treatment of 
comorbidities. 
 
Importantly, PWH commonly report use of CAM(17) and use of CAM is inconsistently captured 
in studies of polypharmacy. In VACS, we found that most patients reported using CAM, 60% of 
whom reported using vitamins and/or minerals, and 13% reported using herbs and/or herbal 
medicine. Similarly, data from an Australian cohort of PWH with HIV viral control (n=522), 
found that second to cardiovascular medications, non-prescription vitamins, minerals, and 
alternative therapies were the most commonly used class of medications(6).  
 
Harms Associated with Polypharmacy Among PWH 
A conceptual model of harm from polypharmacy for PWH includes independent and interacting 
effects of physiologic frailty, drug burden, provider distraction leading to be potentially 
inappropriate medications and omission of indicated medications, and a host of known and 
unknown drug interactions (Figure 1). Physiologic frailty reflects the degree to which organ 
system reserve capacity is lost allowing a relatively minor injury to result in disproportionate 
harm(18). Among both PWH and uninfected individuals, increasing polypharmacy adds to total 
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drug burden and inevitably increases the probability of significant two way and higher order 
drug interactions as well as drug-gene and drug-substance use interactions. Increasing 
physiologic frailty is associated with increasing polypharmacy; increasing polypharmacy can also 
increase physiologic frailty. All these mechanisms may contribute to risk of a host of serious 
adverse events including falls, delirium, pneumonia, hospitalization, and mortality. 
 
Importantly, even if individual effects are mild, additive effects of drugs with overlapping 
activity can be substantial.  A useful approach to quantifying cumulative harmful effects from a 
patient’s entire medication list is to apply indices which score medications according to their 
activity on particular pathways. For example, geriatricians have developed several scoring 
systems to assess clinical manifestations of neurocognitive and functional harms associated 
with anticholinergic medications (19, 20). Both ARV and non-ARV medications may directly 
contribute to mitochondrial toxicity, microbial translocation, and immune dysfunction (21-23). 
Indices could be developed to summarize the level of mitochondrial toxicity, microbial 
translocation, and immune dysfunction conferred by cumulative exposure based on established 
assays. Such indices could be useful for mechanistic research on drug toxicity and to help guide 
ongoing medication selection in the clinical setting. 
 
Potentially Inappropriate Medications and Medication Omissions  
Polypharmacy is linked to poorer prescribing quality including over- (potentially inappropriate 
medications) and under- (medication omissions) prescribing.  Potentially inappropriate 
medications refers to “‘medications [that] have no clear evidence-based indication, carry a 
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substantially higher risk of adverse side effects or [are] not cost-effective (e.g., over-
prescribing)’”(24). Neurocognitively active medications are potentially inappropriate in the 
setting of substantial alcohol use or among those over 65 years of age.  
 
Under-prescribing refers to the lack of prescribing of an effective medication(25). As a patient’s 
problem list and number of medications expands, the provider’s ability to pay attention to each 
condition and its treatment is reduced(26). PWH are less likely to receive recommended 
treatments for disease prevention, such as cardiovascular disease(27, 28). This may be 
particularly problematic in light of increased risk for cardiovascular disease among PWH and 
increasing evidence of benefits from statin use that extend beyond prevention of myocardial 
infarction to prevention of cirrhosis and cancer (29-32).  Similarly, although there is clear 
evidence of harms associated with substance use among PWH(33) and benefits associated with 
its treatment(34-37), several studies indicate that medications to address tobacco, alcohol and 
opioid use are grossly under-prescribed to PWH(38-41). While data support use of medications 
for the treatment of substance use disorders, the risks and benefits of these medications in the 
context of polypharmacy has not yet been rigorously evaluated.  In addition, it is unclear 
whether polypharmacy contributes to under-prescribing of such medications. .     
 
Drug-drug interactions  
Polypharmacy increases the potential for harmful drug-drug interactions (42). Given the effects 
of ARVs on the cytochrome P450 system and transmembrane proteins that act as carriers of 
various medications, there is potential for ARVs to interact with non-ARV drugs across various 
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classes(43). Findings from an Italian cohort of PWH demonstrated that patients with potential 
drug-drug interactions are most commonly receiving protease inhibitor-based ARV regimens 
(62%), followed by non-nucleoside reverse transcriptase inhibitor- (39%) and integrase 
inhibitor- (15%) based regimens (16). In this cohort, non-ARV medications associated with 
concern for drug-drug interactions most commonly included anticoagulant/antiplatelet agents, 
calcium channel blockers, anti-benign prostatic hypertrophy agents, anti-osteoporotic agents, 
and hypnotics/sedatives. Most recently, concern has been raised regarding the potential for 
ARV interactions with over-the-counter agents used to treat obesity(44) (e.g., orlistat), which 
may compromise HIV viral control.  
 
Important considerations for prescribing ARVs in the context of polypharmacy and aging have 
been the subject of comprehensive and recent reviews(45). For example, one review discussed 
the complexities of optimizing cancer treatment in the context of ARVs(46). In addition to 
routine monitoring of organ system function and HIV biomarkers, there is growing awareness of 
the importance of corrected QT (QTc) monitoring given the effects of the non-nucleoside 
reverse transcriptase inhibitors, efavirenz and rilpivirine(9), which may interact with commonly 
prescribed medications (e.g., antibiotics, antipsychotics). PWH were more likely than uninfected 
patients to have evidence of QTc prolongation on electrocardiogram review; 29% of PWH 
demonstrated evidence of QTc prolongation and 6% with extreme prolongation, a finding that 
was driven at least in part by interactions with methadone(47). Importantly, drug-drug 
interactions may result in a “prescribing cascade” whereby additional medications are used to 




Data from a multisite Australian cohort of PWH with HIV viral control found that 3% of 
participants were taking a medication contraindicated with their ARVs(6). These combinations 
most commonly included protease inhibitors with statins, steroids and/or proton pump 
inhibitors and resulted in avoidable symptoms. In this cohort, polypharmacy was independently 
associated with increased risk of diarrhea (aOR [95% CI]= 1.9 [1.1, 3.0]), fatigue (aOR [95% CI]= 
1.7 [1.0, 2.6]) and peripheral neuropathy (aOR [95% CI]= 3.1 [1.8, 5.2])(6).  
 
Drug-gene interactions  
As with drug-drug interactions, an increasing number of medications also increases the 
probability of harmful drug-gene interactions. Drug-gene interactions occur when a patient’s 
genetic profile influences medication efficacy, tolerability, and safety(48). Such variants are 
likely to explain an important component of the relationship between polypharmacy and 
adverse health outcomes. There are now over 100 “actionable” pharmacogenetic interactions 
recommended for clinical management(49, 50). The best known drug-gene interactions in AARV 
is abacavir hypersensitivity among patients with the presence of the major histocompatibility 
complex (MHC) class I allele human leukocyte antigen (HLA)-B*5701(51, 52). Pharmacogenetic 
screening for this allele is a routine clinical practice. More recent evidence suggests that 
polymorphisms in the multidrug resistance protein 1 (MDR1) may predict better viral response 
to efavirenz-containing regimens(53). However, pharmacogenetic testing for this polymorphism 




Drug-Substance Use Interactions 
The current literature is limited in its study of drug-substance use interactions among PWH. Of 
special concern are drug-alcohol interactions because PWH continue to drink alcohol and 
alcohol has substantial overlapping toxic effects with neurocognitively active medications (i.e., 
medications with neurocognitive effects), anticholinergic medications, and medications with 
liver toxicity(55). We looked at concurrent use of alcohol by level of self-report and exposure to 
neurocognitively active and anticholinergic medications known to interact with alcohol in VACS. 
PWH reporting hazardous alcohol consumption were more likely than those reporting low 
levels of consumption to be prescribed a neurocognitive medication (73% vs. 55%) or an 
anticholinergic medication (29% vs. 19%). While it is important to weight the risks and benefits 
of prescribing these medications in the context of alcohol use, we have previously reported that 
these exposures are associated with more frequent hospitalization with delirium or 
dementia(56). Importantly, self-report of alcohol use may be subject to social desirability bias, 
recall bias, and/or impacted by perceptions of societal norms. We have demonstrated that a 
direct biomarker for alcohol exposure (phosphatidylethanol or PEth) is often positive among 
those reporting no current alcohol exposure and this was particularly true among individuals at 
greater risk of injury from alcohol(57). This finding suggests that self-reported alcohol use may 
be least accurate among those at greatest risk of harm from alcohol use. Since alcohol interacts 
widely with medication, verifying the level of alcohol exposure among those taking 
neurocognitively active medications, anticholinergic medications, and/or liver toxic medications 




Of distinct but related concern to alcohol use, is extra-medical use of prescription medications, 
defined as the use of medications for indications other than prescribed, in a manner other than 
prescribed, or without a prescription(12).. In addition to contributing to drug interactions, 
extra-medical use of psychoactive medications, such as prescription opioids, contributes to 
poor HIV outcomes, as well as addiction, overdose, and death(58). In addition, some ARV 
medications, particularly ritonavir for its boosting effects and efavirenz for its neuropsychiatric 
effects, have been used extra-medically(59).  
 
Adverse Events Due to Polypharmacy 
Recent studies heighten concern about polypharmacy. Among patients with and without HIV, 
non-ARV medication count (per five medications) was independently associated with a 19% 
increased risk of serious falls (adjusted odds ratio [aOR] [95% CI] = 1.19 [1.16, 1.22])(60). Among 
PWH, specific medication classes, including benzodiazepines, muscle relaxants, prescription 
opioids, anticonvulsants, and antiarrhythmics, were strongly independently associated with 
increased risk of serious falls. Similarly, we have recently reported that risk for delirium among 
PWH and demographically similar controls is substantially increased after exposure to 
neurocognitive medications and alcohol (56). In a separate set of analyses with careful 
adjustment for baseline severity of illness, we found that receipt of non-ARV polypharmacy was 
associated with a 50% increased risk of hospitalization (adjusted hazard ratio [aHR] [95% CI]= 




Data from the Boston ARCH Cohort Study, a longitudinal cohort of PWH and current substance 
use disorder or lifetime history of injection drug use, has also demonstrated harms associated 
with polypharmacy(61, 62). Of particular concern are findings that demonstrate that each 
additional non-ARV medication was associated with increased risk of past year non-fatal 
overdose (OR [95% CI]=1.07 [1.00, 1.15]), with each additional sedating medication associated 
with increased risk (OR [95% CI]= 1.81 [1.00, 1.39])(61). Taken together, these data suggest that 
polypharmacy is an important and potentially modifiable cause of multiple harms among PWH. 
 
Medication Classes of Particular Concern among PWH 
Given rising rates of opioid overdose deaths among PWH(63), the use of prescribed opioids 
among PWH warrants specific mention(45). It has been consistently documented that opioid 
prescribing alone and with other psychoactive medications is widespread among PWH receiving 
care in diverse settings(64, 65). A recent analysis based on a Canadian cohort found that 27% of 
patients were co-prescribed opioids and benzodiazepines during the study period from 1996 to 
2015(66). This is concerning as prescribed opioids alone and in conjunction with prescribed 
benzodiazepines independently increase risk of mortality after adjusting for medication count 
and disease severity(67).  
 
In addition to causing overdose(61), there is concern that prescribed opioids may contribute to 
infectious complications, which is particularly worrisome for PWH. Extending work based on the 
general population(68-70), we found that prescribed opioids increased risk of community-
acquired pneumonia severe enough to warrant hospitalization(71). This risk was heightened for 
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opioids with known immunosuppressive (e.g., codeine, morphine) properties and with higher 
doses. Whether and how the observed immunosuppressive effects of prescribed opioids result 
in increased risk of other adverse outcomes, such as malignancy, merits investigation. In 
addition, enhanced efforts to decrease opioid prescribing(72) while promoting access to 
indicated treatments for pain(73) and opioid use disorder(74) in HIV treatment settings are 
urgently needed(75-77). 
 
How can we address polypharmacy among PWH? 
Critical elements to address polypharmacy among PWH include: 1) complete medication 
reconciliation; 2) screening, assessment and treatment of substance use; 3) assessment and 
ranking of medications according to risks and benefits; and 4) prioritization and planning with 
the patient(8). In addition, there is growing support for models of care that rely on 
multidisciplinary team members and clinicians. For instance, pharmacist-led evaluations of 
patients with evidence of polypharmacy may help promote safer and appropriate prescribing 
(78). Similarly, drawing from experience with addressing alcohol use among PWH which 
involved bringing social workers, psychologists and psychiatrists into HIV clinics(35, 36), models 
of care that provide on-site geriatric specialty care within HIV treatment settings may be 
critical. In addition, there may be a role for a “stepped care” approach. For instance, patients 
could be seen by a clinical pharmacist and then referred for additional services to a geriatrician 
as needed. Additionally, more work is needed to promote health behaviors, such as physical 
activity, to help prevent development of conditions associated with polypharmacy and treat 




Key Research Priorities  
Future studies should:  
• Accurately catalogue use of non-prescribed medications, including CAM and other over-
the-counter medications as well as extra-medical use of prescription medications, to 
allow for precise measurement and evaluation of the impact of polypharmacy.  
• Develop indices to summarize the level of mitochondrial toxicity, microbial 
translocation, and immune dysfunction conferred by cumulative exposure based on 
established assays as measures of physiologic toxicity.  
• Expand the exploration for drug interactions including drug-drug, drug-gene, and drug-
substance use interactions beyond pairwise interactions in European ancestry samples. 
With the advent of mega biobanks around the world(81, 82), a more comprehensive 
approach with careful external validation is possible. 
• Use direct measures of substance use, especially alcohol, when exploring adverse events 
resulting from drug-substance use interactions. 
• As medical marijuana becomes more widely adopted as an alternative to pain 
management and with legislative changes, further evaluation of how marijuana 
contributes to polypharmacy and impacts health outcomes are needed.   
Conclusion 
The study of polypharmacy, among people with and without HIV infection, is in its infancy. It is 
critical that future research focus on differentiating which medications and which interactions 
are most important, warranting discontinuation among PWH. Criteria for identifying potentially 
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dangerous medications, such as screening tool of older people's prescriptions (STOPP), Beers, 
are helpful for geriatric populations, and the Prescribing Optimally in Middle-aged People’s 
Treatments (PROMPT)(83) may be helpful in middle aged individuals. Criteria tailored for the 
specific needs of PWH – which includes a wide age-span, with greater exposure to substance 
use and even more interactive medications are needed. Until we have a better understanding 
of these issues, it is difficult to design an appropriate randomized trial.  
 
For the time being, much of this work will need to be conducted using real world, observational 
data: large electronic health record datasets linked to pharmacy and genetic data, 
supplemented with direct measures of alcohol and other substance use. However, drug 
interactions are unlikely to comply with the typical assumptions of statistical modeling (linear 
associations, normally distributed). Further, the size and complexity of this kind of data exceeds 
the capacity of conventional approaches.  
 
Expertise in “big data” must be combined with advanced statistical and artificial intelligence 
techniques. Because of concerns regarding confounding by indication(3), these studies must 
adequately account for severity of illness and might do well to focus on outcomes unrelated to 
indications for the medications (e.g., pneumonia, delirium, falls). In the meantime, novel 
interventions providing non-pharmacological treatments (e.g., exercise, smoking cessation) to 
both prevent comorbidity and treat symptoms are needed. Accumulating evidence suggests 
substantial harms from polypharmacy among PWH. As PWH age, these harms are likely to be 
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magnified. While the field has advanced, continued observational and intervention work is 






Key points: (3-5 bullets) 
• Accurate medication reconciliation of prescription, over-the counter, and extra-medical 
medication use is essential.  
• Substance use, especially alcohol use, needs to be accurately assessed and may require 
use of direct biomarkers. 
• Indices summarizing the level of specific toxicity conferred by cumulative exposure are 
needed to guide research and clinical care.  
Expand the exploration for drug interactions including drug-drug, drug-gene, and drug-
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Table 1. Common Medications by HIV Status in FY 2018 in the Veterans Aging Cohort Study 
Class HIV+ Uninfected  
Most Prescribed Medications n 28,104 68,081 
Antihypertensives 56.8% 69.3% lisinopril, amlodipine, metoprolol 
Antilipemic agents 42.0% 50.7% atorvastatin, simvastatin, pravastatin 
Antidepressants 34.4% 37.7% trazodone, sertraline, bupropion 
Non-opioid analgesics 27.7% 32.8% aspirin, acetaminophen 
Nonsalicylate NSAIDs 25.2% 35.1% ibuprofen, meloxiacam, naproxen 
Genito-urinary agents 24.7% 29.2% sildenafil, tadalafil, vardenafil 
Opioid analgesics 22.6% 25.0% hydrocodone, tramadol, oxycodone 
Anticonvulsants 22.0% 27.7% gabapentin, divalproex, lamotrigine 
Gastric agents 21.1% 31.2% omeprazole, pantoprazole, simethicone 
Hypoglycemic agents 13.0% 23.0% metformin, glipizide, saxagliptin 
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Figure 1. Conceptual Model of Harm Associated with Polypharmacy
Notes: To estimate the true effect of polypharmacy, one needs to control for severity of illness to mitigate reverse causality bias or confounding by 
indication. The focus of current research is placed mostly on known pairwise drug interactions and some on drug-gene interactions. More research is 
needed on drug-gene interactions and more complex interactions, including >2 drug and drug-substance use. 
*This list is not exhaustive, but includes common, well-recognized adverse events associated with polypharmacy among people with HIV.
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